ArticleProceedings of the National Academy of Sciences of the United States of America2019
Anti-CD20 therapy depletes activated myelin-specific CD8
Open access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Pooled it
- Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.Neurology(R) neuroimmunology & neuroinflammation · 2023Trial
- Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.Journal of neuroinflammation · 2020Trial
- Ofatumumab in multiple sclerosis: 2-year immune profiling and clinical correlates.Journal of neurology · 2026Observational
- Antigen specificity of clonally enriched CD8Nature immunology · 2026Article
- CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes.Diabetologia · 2026Article
- Evolving role of CD8Frontiers in immunology · 2026Review
- Neuron-reactive KIRNature communications · 2025Article
- In-Depth Characterization of L1CAMInternational journal of molecular sciences · 2025Article
- TDP-43 pathology induces CD8bioRxiv : the preprint server for biology · 2025Article
- CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion.International journal of molecular sciences · 2025Review
- Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell changes in multiple sclerosis.The Journal of clinical investigation · 2025Article
- The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.CNS drugs · 2025Review
- Immune mechanisms and shared immune targets in neurodegenerative diseases.Nature reviews. Neurology · 2025Review
- B Cells Influence Encephalitogenic T Cell Frequency to Myelin Oligodendrocyte Glycoprotein (MOG)38-49 during Full-length MOG Protein-Induced Demyelinating Disease.ImmunoHorizons · 2024Article
- Current Knowledge about CD3International journal of molecular sciences · 2024Review
- Article
- Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics.International journal of molecular sciences · 2024Review
- Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease.Molecular therapy. Methods & clinical development · 2024Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Joseph J SabatinoDepartment of Neurology, University of California, San Francisco, CA 94158; jsabatino@ucsf.neuroimmunol.org zamvil@ucsf.neuroimmunol.org.ORCID 0000-0002-6804-7441
Michael R WilsonDepartment of Neurology, University of California, San Francisco, CA 94158.ORCID 0000-0002-8705-5084
Peter A CalabresiDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-7776-6472
Stephen L HauserDepartment of Neurology, University of California, San Francisco, CA 94158.
Jonathan P SchneckDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21287.
Scott S ZamvilDepartment of Neurology, University of California, San Francisco, CA 94158; jsabatino@ucsf.neuroimmunol.org zamvil@ucsf.neuroimmunol.org.ORCID 0000-0003-2720-9915
University of California, San Francisco · USJohns Hopkins University · US
Funding
The Role of B cells in the Origin and Progression of Multiple SclerosisR35NS111644 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEPHEN L HAUSER · 2019 to 2026
$9.1MNINDS Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25)R25NS070680 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOSEPHSON, SCOTT ANDREW · 2010 to 2023
$6.8MMechanisms by which effector T cells modulate endogenous remyelinationR37NS041435 · NINDS · JOHNS HOPKINS UNIVERSITY · PI CALABRESI, PETER A · 2013 to 2019
$3.0MRepertoire selection of AQP4-specific T cells that cause CNS autoimmunediseaseR01AI131624 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZAMVIL, SCOTT S · 2019 to 2023
$2.2MDisease relevance of CD20 expression on T cells in multiple sclerosis patientsR01NS092835 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L · 2015 to 2018
$1.7MDetection of disease-relevant CD8+ T cells in Multiple SclerosisK08NS107619 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SABATINO, JOSEPH JOHN · 2019 to 2023
$1.0MBD FACSAria II Flow CytometerS10RR028962 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI CAVROIS, MARIELLE · 2011 to 2011
$544kInfluence of NMO gut microbiota on CNS autoantigen-specific T cell responsesR21NS108159 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZAMVIL, SCOTT S · 2018 to 2019
$451kSingle cell RNA-Seq and clonal analysis of CD8+ T cells in MSR21AI142186 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZAMVIL, SCOTT S · 2019 to 2020
$443kNCRR NIH HHS S10 RR028962NIAID NIH HHS R01 AI131624NIAID NIH HHS R21 AI142186NINDS NIH HHS K08 NS107619NINDS NIH HHS R01 NS092835NINDS NIH HHS R21 NS108159NINDS NIH HHS R25 NS070680NINDS NIH HHS R35 NS111644NINDS NIH HHS R37 NS041435
Abstract
CD8
Indexed as
Antigens, CD20CD8-Positive T-LymphocytesMultiple SclerosisAdolescentAdultAntibodies, MonoclonalCells, CulturedFemaleHumansMaleMiddle AgedMyelin ProteinsYoung AdultAntibodies, MonoclonalAntigens, CD20Myelin Proteinsanti-CD20 therapyCD8+ T cellsmultiple sclerosismyelin antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.